Skip to NavigationSkip to content

Johnson & Johnson

US judge slashes Johnson & Johnson damages in Risperdal case

A judge in Philadelphia has reduced the amount of damages Johnson & Johnson was ordered to pay by a jury in October, from $8 million to $6.8 million.

It relates to the company allegedly downplaying risks that the antipsychotic Risperdal (risperidone) could lead to gynecomastia. In a statement, Johnson & Johnson said that the ruling was appropriate in reducing “the excessive punitive damages award.” The company are still seeking to get the verdict completely overturned.

No link between talc and ovarian cancer, new study reveals

Researchers examining data from over 252,000 women have concluded that there is no statistically significant link between the use of talc-based baby powder and ovarian cancer.

The research was published in the Journal of the American Medical Association. It found that the use of powder in the genital area and incidents of ovarian cancer was 1.08. 2,168 women in the study developed ovarian cancer.

J&J's CAR-T candidate boasts 100% response rate in relapsed or refractory multiple myeloma

Johnson & Johnson were present at the American Society of Hematology (ASH) Annual Meeting over the weekend to unveil new data on its B cell maturation antigen (BCMA)-directed chimeric antigen receptor T cell (CAR-T) therapy JNJ-4528 in the treatment of relapsed or refractory multiple myeloma (MM).

The study focused on MM patients who had received at least three prior lines of therapy or were double refractory to a proteasome inhibitor (PI) and an immunomodulatory drug (IMiD); had received a PI, IMiD and an anti-CD38 antibody.

J&J to supply 500,000 Ebola vaccines to fight DR Congo outbreak

Johnson & Johnson has reached an agreement with the Government of the Democratic Republic of the Congo (DRC) to supply up to 500,000 regimens of its Ebola virus vaccine in an effort to aid an expanded public health initiative to help battle the ongoing outbreak of the disease in the country.

The current outbreak in DRC is the second-worst on record after the 2014-2016 West Africa epidemic; to date, more than 3,000 cases have been reported and 2,000 patients have died.

J&J must pay $572 million for fuelling opioid crisis in Oklahoma, judge says

A judge in Oklahoma has said that Johnson & Johnson must pay $572 million for the part it played in fuelling the opioid crisis which kills more than 130 a day in the United States.

Cleveland County District Judge Thad Balkman has said Johnson & Johnson must pay the state of Oklahoma $572,102,028, after Oklahoma prosecutors demanded more than $17 billion in payment over the role the firm played in worsening the opioid crisis through aggressively marketing opioid drugs.

J&J's ponesimod meets primary and secondary endpoints at Phase 3 in relapsing multiple sclerosis

New Phase 3 data has been released on Johnson & Johnson’s selective sphingosine-1-phosphate receptor 1 (S1P1) modulator ponesimod, reporting that the drug performed favourably compared to Genzyme’s Aubagio (teriflunomide) in the treatment of adult patients with relapsing multiple sclerosis.

J&J 'worse' than Purdue Pharma expert witness says

The role Johnson & Johnson played in the opioid crisis was ‘in some ways worse’ than that of Purdue Pharma, an expert witness said in the Oklahoma trial of J&J.

Dr Andrew Kolodny, the co-director of the Opioid Policy Research Collaborative at Brandeis University, has said that healthcare conglomerate J&J may have played a bigger role in the opioid crisis than the Sackler owned firm Purdue Pharma.

Janssen closes plant in California, 49 positions axed

Janssen are letting go of 49 employees due to the closure of their plant in Vacaville, California.

The Johnson & Johnson subsidiary took over the plant in 2001, after the healthcare conglomerate acquired the Palo Alto-based ALZA Corporation for $10.5 billion.

However the permanent closure will see 49 workers lose their jobs, as Janssen announced their decision to close the Vacaville facility. The firm said that the plant was no longer needed due to a shift in focus towards other areas.

Indian authorities say J&J's baby shampoo contains 'harmful ingredients'

Indian authorities in the state of Rajasthan have said that samples taken from Johnson & Johnson’s baby shampoo contained ‘harmful ingredients.’

The Rajasthan Drugs Control Organisation's said in a notice date 5 March, that samples of J&J’s baby shampoo had failed quality tests. The US healthcare conglomerate rejected the claims.

J&J bows to PETA pressure and drops forced swim tests in mice

Johnson & Johnson has announced it is to end its practice of forced swim tests on mice, rats and other animals in the research of new drug treatments, following discussion with animal rights advocacy group PETA. The company’s pledge means it will not use the test from now on in either its own or external laboratories.

Forced swimming tests – or behavioural despair tests, as they are also known – involve placing a mouse or rat in an acrylic cylinder from which they cannot escape as it slowly fills with water.

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches